Replies

DHS, immunotherapy medicines like Keytruda and Opdivo are very much mainstream, and they're approved by the FDA and other regulatory bodies. As a said previously, Keytruda is actually submitting data to become a first-line treatment for lung cancer, meaning that it could change the protocols for treating certain types of cancers to use Keytruda first.

You also made my other points, by acknowledging how tricky cancers are, especially when they metasticize. Cancers ARE genetically-adept, mutating and becoming resistant to treatments over time. This is why immunotherapy and targeted treatments are so promising, because the body's own immune system can be very powerful in warding off cellular over-growth.

Yes, a significant number of dollars have been spent over the past half-century, but progress has been made. The body of knowledge surrounding cancer has advanced exponentially. New ways of treating cancers have emerged, followed by new medicines. There are success stories for many patients.

But cancer research and success isn't a goal line; it's a journey. There isn't a one-size-fits-all treatment. Sometimes, we learn things that make us change course drastically in our approach to treatment. If it were easy, we'd already have done it.

Yet, what is their efficacy? Versus chemo, radiation, and surgery?

So, just now and after 50 years other treatments are becoming available. Yeah! Okay, good news and finally! Keeping with my high expectations, whats up next? There are probably hundreds of types of cancer and people are suffering.

Again, the Achilles heel for cancer is preventing it from spreading. Or at least, that is the biggest bang for the buck (IHMO)... and maybe the hardest. Maybe the immune system can be tasked.